Difloxacin (A-56619) and A-56620 are synthetic novel aryl-fluoroquinolones effective in the treatment of experimentally induced aerobic bacterial infections (5) , but their effect on anaerobic bacterial infections is not known. Among the newly discovered quinolones, ciprofloxacin is active against Bacteroides fragilis and other anaerobes at 4 to 8 p.g/ml (12) . Difloxacin and A-56620 are also active against anaerobic bacteria (P. B. Fernandes, J. Weisz, R. Bower, N. Shipkowitz, K. Jarvis, and A. Pernet, Program Abstr. 24th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 77, 1984) . Another compound, A-60969, also a fluoroquinolone, was recently shown to be active against anaerobic bacteria (J. Stamm, C. Vojtko, J. Weisz, C. Hanson, D. T. W. Chu, and P. B. Fernandes, 25th ICAAC, abstr. no. 132, 1985) . Quinolones that are inactive against B. fragilis include enoxacin (13) , WIN 49375 (9), cinoxacin (7), norfloxacin (10) , and nalidixic acid (12) . In our laboratory, difloxacin and A-56620 were tested against anaerobic bacteria and were found to be active against 90% of B. fragilis isolates at 4 p.g/ml or less (M. B. Bansal, D. V. Martin, and H. Thadepalli, 25th ICAAC, abstr. no. 571, 1985) . Therefore, we tested the efficacy of these two new quinolones in the treatment of experimentally induced B. fragilis-associated intra-abdominal abscess in rats. The therapeutic responses were compared with those of ciprofloxacin and other drug regimens proven to be effective in such infections, such as cefoxitin given alone or the combination of clindamycin and gentamicin.
MATERIALS AND METHODS
Male Wistar rats (Simonsen Laboratories, Gilroy, Calif.), weighing 250 to 300 g, were used for this study. isolates to difloxacin, A-56620, and other drugs were determined before the beginning of the study ( Table 1 ). The MICs for B. fragilis were determined by the agar dilution method as previously described (1, 14) . The susceptibility of E. coli was determined by the macrobroth dilution method described elsewhere (15) . Before use, both E. coli and B. fragilis were passaged through the peritoneal cavity of a rat. B. fragilis was cultured in prereduced peptone-yeast-glucose broth, and E. coli was cultured in brain heart infusion broth. All incubations were done at 37°C. An anaerobic glove box was used for isolation, culture, and determination of the MICs of the antibiotics for B. fragilis.
Antibiotic therapy was started 4 h after inoculation. All drugs were injected intramuscularly three times a day at 4-h intervals. The animals were treated in six different groups, including a control group that was inoculated with bacteria but left untreated and five groups treated with antibiotics. The five antibiotic groups were treated with difloxacin, A-56620, ciprofloxacin (Miles Laboratories, Inc., West Haven, Conn.), cefoxitin (Merck, Sharp & Dohme, West Point, Pa.), or clindamycin (The Upjohn Co., Kalamazoo, Mich.) with gentamicin (Elkins-Sinn Inc., Cherry Hill, N.J.). All the groups, including the controls, were treated concurrently.
The doses used in this study were: cefoxitin, 130 mg/kg of body weight; clindamycin, 75 mg/kg; gentamicin, 20 mg/kg; and 40 mg/kg for each of the three quinolones, difloxacin, A-56620, and ciprofloxacin. The doses of cefoxitin, clindamycin, and gentamicin used were based on previously reported experimental studies in similar animal models (2, 11, 17) . The doses of difloxacin and A-56620 were arbitrarily chosen as 40 mg/kg based on our previous experience with ciprofloxacin (2) .
The levels of difloxacin and A-56620 in serum were determined by bioassay with E. coli ATCC 25922 as the test organism by using a method described by Bennett et 
al. (3).
A group of eight animals was used for each drug and dose. The animals were bled by cardiac puncture at indicated intervals (see Table 3 ). The levels of the drugs in the peritoneal fluid were determined as follows. The animals were injected with 3 ml of 5% thioglycolate, and 48 h later they were given 40 mg of the quinolone drug tested per kg. Peritoneal fluid samples were obtained at fixed intervals, and the drug levels were determined by methods described NEW FLUOROQUINOLONES AGAINST B. FRAGILIS ABSCESS above. Drug levels in peritoneal fluid after an 80-mg/kg dose were not studied because this high dose was not used in the abdominal-abscess experiment. The dose of antibiotics used was generally six times the recommended high therapeutic dose for humans. Six times the dose is necessary to achieve the levels in serum achieved in humans because of the rapid excretion of drugs which is known to occur in small animals with a small surface area (6). All animals were treated for 13 days and euthanized on day 14. The abdomens of the animals were then opened and examined for abscesses. Pus was obtained and cultured for both E. coli and B. fragilis; E. coli was identified by the conventional scheme, and B. fragilis was identified by methods described elsewhere (8) .
In this study, only animals that had no cultivable organisms in the abdominal pus were considered cured, and those that grew either of the organisms used in the inoculum were considered to have failed treatment. A mere decline in numbers of organisms was not considered adequate; total elimination of the inoculated organisms was required for an antibiotic to be called therapeutically effective.
RESULTS
The MICs of the antibiotics against the test isolates used in this study are shown in Table 1 . The MIC of difloxacin was 8 ,ug/ml against B. fragilis, whereas the MIC of ciprofloxacin and A-56620 was 4 ,ug/ml. E. coli was susceptible to all three quinolones at <2 ,ug/ml.
The therapeutic results for all three quinolones tested are shown in Table 2 . All control animals that received no antibiotic treatment developed abscesses and grew E. coli on culture of pus; about 85% of them also grew B. fragilis. In contrast, none of the animals treated with clindamycingentamicin grew B. fragilis or E. coli, although some of them and cleared all 27 animals of infection. A-56620 also eliminated E. coli from all 27 animals treated in two successive batches, although it failed to eliminate B. fragilis from 3 of 13 animals in experiment 1 and 1 of 14 in experiment 2. However, these differences were not statistically significant.
In comparison, difloxacin as a single drug in these experiments was as effective as the clindamycin-gentamicin therapy; both antibiotic regimens were almost 100% effective. Ciprofloxacin and cefoxitin were both 90% effective.
The levels in serum and peritoneal fluid of difloxacin and A-56620 are shown in Table 3 . After a single 40-mg/kg dose, the achieved level in serum of difloxacin was about 14 ,ug/ml after 1 h and around 8 p.g/ml after 2 h. The level of difloxacin in the peritoneal fluid was about 8 Fxg/ml 1 h after a 40-mg/kg dose. The levels of A-56620 in serum and peritoneal fluid at 40 mg/kg were around 2 pLg/ml at 1 h. When the doses of difloxacin and A-56620 were increased to 80 mg/kg, the levels in serum almost doubled half an hour later. The half-life of difloxacin in rats is about 5 h, and the half-life is 3 h for A-56620 (information from Abbott Laboratories, North Chicago, Ill.). In other experiments, it was found that a single dose of 40 mg of ciprofloxacin per kg produced a mean peak level in serum of 1.7 ± 0.65 ,ug/ml. The serum half-life of ciprofloxacin is 3 to 5 h (information from Miles Laboratories). In this study, the level of gentamicin in serum was found to be 5.1 ,ug/ml 1 h after a 20-mg/kg dose (data not shown).
Other investigators reported earlier that a dose of 130 mg of cefoxitin per kg produced levels in serum of 75 ,ug/ml in rats 1 h after injection (12) . The dose of 75 mg of clindamycin per kg, which we used in rats, was previously reported to reach a peak average level in serum of 5.5 ,ug/ml (17) . DISCUSSION The results of our study demonstrate that difloxacin and A-56620 are effective in the treatment of B. fragilisassociated experimental abdominal abscess. The data further indicate that these aryl-fluoroquinolones are as effective as cefoxitin and are comparable to clindamycin-gentamicin therapy. Ciprofloxacin was as effective as cefoxitin in a similar experimental infection (2). Our results with ciprofloxacin were in agreement with the previous report.
Difloxacin achieved good levels in serum and peritoneal fluid, and these levels were above the in vitro difloxacin MICs (90%) for B. fragilis and E. coli. This may explain the high efficacy of difloxacin in our experimental model. The in vivo activities of A-56620 and ciprofloxacin were much greater than would be expected on the basis of their in vivo levels in serum. These two drugs achieved low levels in serum (2 Fxg/ml), adequate to cover E. coli but far below their VOL. 30, 1986 ANTIMICROB. AGENTS CHEMOTHER. 
